ESSA Pharma Inc
(TSX Venture Exchange : EPIX)

( )
EPIX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Company
0.00%45.801.4%$861.47m
JNJJohnson & Johnson
-0.01%138.520.7%$789.69m
PFEPfizer Inc.
0.35%40.010.9%$772.06m
MRKMerck & Co., Inc.
0.43%74.200.6%$746.51m
LLYEli Lilly and Company
-0.03%116.401.0%$728.89m
ABBVAbbVie, Inc.
0.21%78.122.2%$383.52m
AZNAstraZeneca PLC Sponsored ADR
0.08%38.801.3%$239.39m
NVSNovartis AG Sponsored ADR
-0.13%77.190.2%$229.98m
GSKGlaxoSmithKline plc Sponsored ADR
-0.20%39.900.2%$99.87m
NVONovo Nordisk A/S Sponsored ADR Class B
-1.82%48.510.1%$66.85m
SNYSanofi Sponsored ADR
-0.02%41.080.2%$39.44m
LCILannett Company, Inc.
1.14%7.1236.7%$7.83m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.81%3.111.6%$1.08m
EPIXESSA Pharma Inc
3.11%2.490.1%$0.03m

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.